Curative effect of Daglipzin combined with neoactin in the treatment of heart failure after acute myocar-dial infarction
Zhang Lifang
Li Runjun
Gao Junjie
Tang Xiuying
Abstract：Objective To explore the curative effect of Daglipzin combined with neoactin in the treatment of heart failure(HF)after acute myocardial infarction(AMI).Methods According to the random number table method,248 patients with HF after AMI admitted to the First Hospital of Qinhuangdao from April 2020 to March 2022 were divided into two groups,namely the control group(124 patients)and the combination group(124 patients).The control group was given neoactive therapy on the basis of conventional treatment[first with 1.5 μ g/kg intravenous infusion,3～5 minutes after infusion at a rate of 0.0075～0.01 μ g/(kg·min)continued intravenous infusion];The combination group was treated with dagliaglozin(10 mg/time once a day)on the basis of the control group,and both groups were treated continuously for 3 days.Clinical efficacy,cardiac function indexes(left ventricular ejection fraction,left ventricular end-diastolic diameter,left ventricular end-systolic diameter),myocardial injury markers(cardiac troponin I,aminoterminal brain natriuretic peptide precursor,alpha-hydroxybutyrate dehydrogenase)and adverse reactions(headache,nausea and vomiting,hypotension)were compared between the two groups after treatment.Results There was no significant difference in gender,age,body mass index and the number of patients undergoing percutaneous coronary intervention(PCI)between the two groups(P＞0.05).The total clinical effective rate of the combined group was 96.77％(120/124),which was significantly higher than that of the control group 79.03％(98/124)(P＜0.05).After treatment,left ventricular ejection fraction(LVEF)was increased in both groups,and the LVEF in the combination group was higher(P＜0.05).After treatment,the levels of left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)in both groups were decreased,and the levels of the combined group were lower(P＜0.05).After treatment,the serum levels of cardiac troponin Ⅰ(cTnⅠ),amino terminal brain natriuretic peptide precursor(NT-proBNP)and α-hydroxybutyrate dehydrogenase(α-HBDH)in both groups were decreased,and the levels of cTnⅠ,NT-proBNP and α-HBDH in the combined group were lower(P＜0.05).There was no significant difference in adverse reactions between the control group and the combined group(P＞0.05).Conclusion Daglizin combined with neoactin in the treatment of patients with heart failure after acute myocardial infarction has high efficacy and safety,can improve the level of cardiac function in cases with HF after AMI,and reduce the level of myocardial markers in cases with HF after AMI,which is worthy of clinical promotion.
Keywords：Acute myocardial infarctionHeart failureDaglizinNeoactivinMyocardial injury
Publication Date：2024-10-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1227-1230 )